A structured, non-judgmental interview protocol for uncovering true medication-taking behavior, identifying the specific barrier, and matching it to the right intervention
How an adherence interview opens determines whether the rest of it produces useful information. Patients routinely under-report missed doses because they anticipate disapproval — a phenomenon well documented as social desirability bias. A structured adherence interview begins by normalizing non-adherence explicitly, signaling that the clinician already expects some doses to be missed and is not there to judge, only to help.
Adherence interviewing is uniquely vulnerable to response bias because the behavior being measured — skipping medication — is exactly the behavior patients feel they are expected to avoid. If a clinician opens with a question that implies an expected correct answer ("You have been taking your medication, right?"), the patient's incentive shifts from accurate reporting to social conformity.
A non-judgmental opening reverses that incentive. Framing such as "Many people find it hard to take every dose of every medication exactly as prescribed — how has it been going for you?" does three things simultaneously:
• Normalizes the behavior: missing doses is presented as common and expected, not a failure • Signals psychological safety: the clinician is asking to help problem-solve, not to catch a mistake • Removes the binary framing: there is no implied "right answer" of perfect adherence
This single framing choice has outsized downstream effects: interviews that open non-judgmentally elicit substantially more disclosed missed doses than interviews that open with a direct compliance check, even when the same patient is asked both ways in the same visit.
Before any adherence-specific question is asked, the structured interview typically establishes rapport and context: confirming which medications the patient believes they are taking, what each is for in the patient's own words, and any recent changes to the regimen. This serves two purposes — it surfaces basic knowledge gaps that themselves predict nonadherence, and it gives the patient time to become comfortable before more sensitive questions arrive.
Tone and pacing matter as much as wording. A rushed, checklist-style delivery of a "normalizing" sentence can undercut its own intent; the same words delivered unhurriedly, with eye contact and a genuinely curious tone, land very differently. Clinicians are trained to slow down specifically at this transition point in the visit.
The single most common adherence assessment in practice — "Are you taking your medication as prescribed?" — is also one of the least accurate. A binary yes/no screen invites a binary socially desirable answer. Asking the patient to describe, concretely, how they actually take each medication on a typical day reveals gaps that a yes/no question systematically misses.
A yes/no adherence question compresses a highly variable behavior — dose timing, missed doses, drug holidays, splitting pills to stretch supply — into a single binary. Patients who miss doses only occasionally, or who are broadly adherent but consistently late by hours, will typically answer "yes" because the question does not invite the nuance needed to answer otherwise.
The result is a systematic overestimate of true adherence. Clinicians who rely solely on a yes/no screen risk missing patients who would benefit most from intervention, because those patients look adherent on paper.
Rather than asking whether the patient adheres, the structured interview asks the patient to narrate how they actually take each medication:
• "Walk me through yesterday — when did you take each of your medications?" • "How many times in the last week do you think you missed a dose, even by a little?" • "Is there a medication that's harder to remember or harder to take than the others?"
This approach surfaces specifics a yes/no screen cannot: which medication is skipped (often the one perceived as least important), what time of day doses are missed (commonly the midday dose, associated with work or school schedules), and whether the patient has developed workarounds — splitting tablets, stockpiling, or spacing refills to save cost — that a compliance checkbox would never reveal.
Even well-conducted open-ended interviews benefit from triangulation. Pharmacy refill timing (proportion of days covered), pill counts at follow-up visits, and — where available — electronic pill-bottle monitoring all provide an objective check against self-report. Discrepancies between what a patient describes and what refill data shows are not treated as a patient being untruthful, but as a prompt to explore further: a gap often reflects an unspoken barrier the interview has not yet uncovered.
A structured open-ended interview does not replace objective adherence data — it explains it. Refill records can show that doses are missed; only a well-run conversation can reveal why.
Nonadherence is not one problem — it is several different problems that happen to look similar from the outside. A structured interview systematically probes across recognized barrier categories, because a patient who cannot afford a medication needs a fundamentally different response than a patient who forgets doses or who distrusts the diagnosis behind the prescription.
Once open-ended questioning has surfaced that a gap exists, the interview shifts to characterizing why. Four broad, non-exclusive categories are screened in sequence:
• Cost: Is the copay, deductible, or total out-of-pocket cost causing the patient to skip doses, split pills, or delay refills? • Side effects: Is a bothersome or frightening side effect — nausea, fatigue, sexual dysfunction, dizziness — driving avoidance, even if unreported at prior visits? • Forgetting / regimen complexity: Is the number of daily doses, pill burden, or lack of a routine (e.g., irregular work shifts) the primary driver, independent of belief or affordability? • Health beliefs and concerns: Does the patient doubt the diagnosis, question whether the medication is truly needed, worry about long-term dependence, or hold beliefs about the condition that conflict with continuous treatment?
These categories are not mutually exclusive — a patient may face two or three simultaneously — but identifying which is dominant changes what the clinician does next.
Generic questions ("why do you miss doses?") often produce generic, unhelpful answers ("I just forget"). Targeted probes surface the actual driver:
• Cost: "Has the cost of any of these ever made you put off filling a prescription?" • Side effects: "Does anything about taking this medication feel unpleasant or worrying?" • Forgetting/complexity: "Is there a time of day or a routine where taking this is harder to remember?" • Beliefs: "What is your own sense of why this medication was prescribed, and how necessary it is right now?"
The interviewer listens for which category the patient's answers cluster around, rather than assuming a single default explanation such as forgetfulness — the most commonly assumed but not always the most common actual cause.
The most common failure in adherence counseling is a mismatch: a generic "try to remember to take your pills" message delivered regardless of the actual barrier. A structured approach routes each identified barrier to a specific, appropriate response — because a cost problem is not solved by a reminder app, and a forgetting problem is not solved by a discount card.
Once the dominant barrier is identified, the intervention is chosen to target it directly:
• Cost barrier → cost-reduction pathway: switching to a lower-cost generic or therapeutic equivalent, connecting the patient with manufacturer or pharmacy assistance programs, or adjusting regimen to reduce the number of costly agents. • Side-effect barrier → tolerability pathway: adjusting dose or timing, switching within a drug class to a better-tolerated agent, or adding a mitigating treatment for the side effect itself, paired with clear counseling on what to expect and when to call rather than silently stop. • Forgetting / complexity barrier → simplification pathway: reducing dosing frequency where clinically possible, consolidating multiple medications into combination products, and pairing the regimen with concrete cues — pillboxes, phone alarms, linking doses to an existing daily habit. • Health-beliefs barrier → motivational pathway: this is not a logistics fix but a conversation — exploring the patient's specific concerns, correcting misunderstandings, and using shared decision-making rather than simply repeating the recommendation more forcefully.
A generic "you really need to take this every day" message assumes the barrier is motivation or willpower, which is frequently not the actual barrier at all. When the true barrier is cost, generic encouragement is not merely unhelpful — it can feel dismissive, since the patient already wants to take the medication but cannot afford to. When the true barrier is a side effect, generic encouragement without acknowledgment risks the patient concluding the clinician does not take their experience seriously and disengaging altogether.
Tailored intervention, by contrast, demonstrates that the earlier open-ended questioning actually changed the plan — which itself reinforces trust and makes the patient more likely to disclose accurately at the next visit.
The intervention should be visibly traceable back to what the patient said in stages 2 and 3. If a patient describes a cost barrier and receives a reminder app, the mismatch signals the interview information was not used — undermining the value of having asked in the first place.
An interview and an intervention are only half of the adherence-improvement cycle. Without a scheduled follow-up contact, there is no way to know whether the tailored intervention actually changed behavior — or whether it addressed the wrong barrier, was not implemented by the patient, or needs to be adjusted further.
A follow-up contact — by phone, patient portal message, or a short visit — revisits the same open-ended style used in the original interview, now focused specifically on the intervention that was put in place:
• Was the intervention actually implemented (did the patient get the assistance program approved, start the pillbox, receive the dose adjustment)? • Has the originally identified barrier improved, stayed the same, or been replaced by a new one? • Has adherence, described concretely rather than as a yes/no, improved since the intervention began?
This mirrors the same non-judgmental, open-ended structure from stages 1 and 2 — the follow-up is itself a smaller version of the full interview, not a simple compliance check.
It is common for an initial intervention to be only partially effective, or to reveal a second barrier that was masked by the first. A patient whose cost barrier was resolved may then reveal a forgetting barrier that was always present but never came up because cost dominated the earlier conversation. The follow-up interview should be prepared to re-run the barrier-identification step rather than assuming the case is closed once one intervention has been tried.
Because adherence is not a fixed trait but a behavior that fluctuates with life circumstances, insurance changes, new side effects, or shifts in health beliefs, periodic reassessment — not a single one-time fix — is what sustains improved adherence over the long term.